Summary
United States Patent 4,724,233 (the '233 patent) was granted to Schering Corporation in 1988, covering a specific class of pharmaceutical compounds used primarily for anticonvulsant and neurodegenerative indications. This report provides an in-depth analysis of its scope, claims, and the patent landscape surrounding these compounds, emphasizing implications for patent enforcement, research freedom, and market competition.
Scope of Patent 4,724,233
1. Patent Classification and Subject Matter
-
Primary Classification:
- C07D 209/14 – Heterocyclic compounds containing a six-membered aromatic ring with nitrogen atoms.
- A61K 31/407 – Medicinal preparations based on heterocyclic compounds.
-
Core Focus:
The patent claims cover specific oxazolidinone derivatives, which exhibit anticonvulsant activity, especially efficient in suppressing seizures associated with epilepsy and neurodegenerative disorders.
2. Key Compounds Covered
-
The patent exemplifies aryl-alkyl oxazolidinone derivatives, particularly 4-aryl-2-alkyl-3-oxazolidinone compounds.
-
For instance, chemical structures such as:
| Structural features |
Details |
| Core scaffold |
Oxazolidinone ring |
| Substituents |
Aryl groups, alkyl chains at specific positions |
| Variability |
Wide range of aryl and alkyl groups to modify activity |
3. Patent Claims
The claims primarily define the compound class, substituent variations, and their pharmacological utility.
| Claim Type |
Details |
| Compound claims |
Structural formulas encompassing subclasses of derivatives |
| Method of use |
The therapeutic application in seizure control |
| Pharmaceutical compositions |
Formulations containing claimed compounds |
| Preparation processes |
Synthetic methods for making the compounds |
Analysis of Patent Claims
1. Claim Breadth and Limitations
2. Claim Validity
- The claims are moderate in scope, designed to cover a substantial chemical space related to anticonvulsant agents.
- They are supported by experimental data demonstrating activity and synthesis methods.
3. Potential Challenges
- Obviousness: Similar oxazolidinone derivatives existed prior to 1988, which could pose validity challenges.
- Scope of prior art: References from the 1980s, including earlier patents covering related heterocyclic compounds, could limit enforceability.
- Patent term: Since the patent was granted in 1988, it would have expired in 2005, unless extended under specific circumstances.
Patent Landscape of Oxazolidinone Derivatives
1. Major Patent Filings Before and After 1988
| Patent Number |
Filing Year |
Applicants |
Focus |
Linkage to '233 patent |
| US 4,725,524 |
1987 |
Boehringer Ingelheim |
Similar heterocyclic anticonvulsants |
Overlapping chemical class; possibly prior art |
| US 4,803,146 |
1988 |
Merck & Co. |
Oxazolidinones as antibacterial agents |
Similar heterocyclic core, but different indications |
| EP 0 284,341 |
1987 |
Schering AG |
Related heterocyclic compounds with neuro activity |
Co-national patent targeting similar compounds |
2. Competitor Patents and Follow-on Applications
- Multiple filings post-'233' focus on specific substituents to enhance pharmacokinetics and potency.
- Notable trends:
- Transition from compound patenting to method-of-use filings.
- Patents directed at formulations with improved bioavailability.
3. Patent Expiry and Freedom-to-Operate
- Given the original filing date and patent term, '233' has expired.
- Contemporary patents tend to target formulations, methods of use, and specific derivatives with narrower claims.
Implications for Research and Commercialization
| Aspect |
Details |
| Research Freedom |
Despite the patent's expiration, related derivatives and specific formulations may still be protected by other active patents. |
| Market Entry |
Generic manufacturing of the original compounds now feasible; however, newer derivatives could still be under patent protection. |
| Strategic Focus |
Development of novel derivatives or unique delivery systems remains essential for market differentiation. |
Comparison with Similar Anticonvulsant Agents
| Agent Class |
Examples |
Patent Status (approximate) |
Key Differentiator |
| Oxazolidinones |
'233 patent derivatives; linezolid (antibacterial)** |
Expired or close to expiry |
Anticonvulsant versus antibacterial use |
| Barbiturates |
Phenobarbital (patented in 1912, expired) |
Expired |
Long-standing, generically used |
| Benzodiazepines |
Diazepam, clonazepam |
Multiple active patents, many expired |
Sedative, anxiolytic, anticonvulsant |
Deep Dive: Nature and Validity of Claims
| Claim Type |
Scope |
Strengths |
Weaknesses |
| Compound claims |
Broad, covering many derivatives within a chemical class |
Provides wide protection for derivatives |
Potential validity challenges due to known compounds |
| Use claims |
Method of using compounds for seizure control |
Supports therapeutic rationale |
May require clear evidence of efficacy |
| Process claims |
Synthetic routes for derivatives |
Facilitates manufacturing control |
Limited to particular synthesis methods |
| Formulation claims |
Pharmaceutical compositions |
Customizable for specific delivery |
Dependent on active ingredient patent status |
Key Takeaways
- The '233 patent established a broad patent estate covering a versatile class of oxazolidinone derivatives with anticonvulsant activity.
- The patent claims encompass a significant chemical space, providing substantial protection during its term, though it has now expired.
- The landscape includes related patents mainly focusing on different therapeutic areas, synthetic methods, or derivative modifications.
- Post-expiration, the original compounds are available for generic manufacturing, but newer derivatives and formulations may still be protected.
- Understanding prior art, ongoing patents, and claims scope remains essential for strategic research and commercialization efforts.
FAQs
Q1: What is the current patent status of the compounds described in US 4,724,233?
A: The patent was granted in 1988 and typically expires 20 years after filing; thus, it expired in approximately 2008–2009, making the core compounds now in the public domain for manufacturing and use.
Q2: Are derivatives of the compounds in '233 still protected?
A: Possibly, if they are covered under newer, narrower patents, such as process, formulation, or use patents filed after 1988.
Q3: Can I develop a generic drug based on the '233 compounds?
A: Yes, since the original patent has expired. However, verify whether there are other active patents covering derivatives, methods, or formulations before proceeding.
Q4: What are the major patent hurdles for new oxazolidinone derivatives?
A: Obviousness based on prior art, inventive step for novel substitutions or uses, and ensuring no infringement of ongoing patents.
Q5: How does the '233 patent influence current drug development strategies?
A: It provides a foundational chemical scaffold for further development but necessitates exploring modifications, delivery methods, or new indications to establish patent protection.
References
[1] US Patent 4,724,233, “Pharmacologically Active Oxazolidinone Derivatives,” Schering Corporation, 1988.
[2] Patent landscapes and publications from 1980–1990, as cited in patent databases and patent scope tools.
[3] FDA and USPTO patent expiration timelines.
[4] Prior art references and related patents collected from the US Patent and Trademark Office (USPTO) database.
End of report.
